SEC Form 4 · accession 0001209191-15-060993
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Charles Lubner
Officer — SVP and CFO
Period of report
Jul 14, 2015
Accepted (ET)
Jul 15, 2015 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 14, 2015 | M | 5,799 | $2.03 | A | 75,069 | D | |
| Common StockF1 | Jul 14, 2015 | M | 1,701 | $7.94 | A | 76,770 | D | |
| Common StockF1,F2 | Jul 14, 2015 | S | 7,500 | $48.92 | D | 69,270 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F3 | $2.03 | Jul 14, 2015 | M | 5,799 | D | — | Jun 5, 2022 | Common Stock | 5,799 | 13,744 | D |
| Employee Stock Option (right to buy)F1,F4 | $7.94 | Jul 14, 2015 | M | 1,701 | D | — | May 14, 2023 | Common Stock | 1,701 | 133,299 | D |
Explanation of responses
- F1The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2015.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $48.31 to $49.01 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3This option vests as to 6.25% of the shares on September 6, 2012 and further vests as to 6.25% of the shares at the end of each of successive three-month period thereafter until June 6, 2016.
- F4This option vests as to 25% of the shares on May 15, 2014 and further vests as to 6.25% of the shares at the end of each of successive three-month period thereafter until May 15, 2017.